Advances in therapy for melanoma brain metastases

Clinics in Dermatology

Volumn 31, Issue 3, 2013, Pages 264-281

  Flanigan, Jaclyn C ^a   Jilaveanu, Lucia B ^a   Chiang, Veronica L ^b   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; B RAF KINASE; CARMUSTINE; DABRAFENIB; DACARBAZINE; FOTEMUSTINE; INTERLEUKIN 2; IPILIMUMAB; LOMUSTINE; SORAFENIB; TEMOZOLOMIDE; VEMURAFENIB;

ARTICLE; BLEEDING; BLOOD BRAIN BARRIER; BRAF GENE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN TUMOR; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER STAGING; CENTRAL NERVOUS SYSTEM DISEASE; CENTRAL NERVOUS SYSTEM METASTASIS; CEREBELLUM DISEASE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONVULSION; CRANIOTOMY; DIZZINESS; DRUG INDUCED HEADACHE; DRUG MEGADOSE; GAMMA KNIFE RADIOSURGERY; GENE MUTATION; HEADACHE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; KARNOFSKY PERFORMANCE STATUS; LASER INTERSTITIAL THERMOCOAGULATION THERAPY; LEUKOENCEPHALOPATHY; LIVER METASTASIS; LOW LEVEL LASER THERAPY; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE N RAS; OVERALL SURVIVAL; PARTIAL BODY RADIATION; POSTOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION NECROSIS; RISK FACTOR; STEREOTACTIC RADIOSURGERY; TUMOR BLEEDING; TUMOR VOLUME; WHOLE BRAIN RADIOTHERAPY;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; HUMANS; MELANOMA; PROGNOSIS; RADIOSURGERY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84876706330     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2012.08.008     Document Type: Article

References (99)

1. DiLuna M.L., King J.T., Knisely J.P., Chiang V.L. Prognostic factors for survival after stereotactic radiosurgery vary with the number of cerebral metastases. Cancer 2007, 109:135-145.
2. Barnholtz-Sloan J.S., Sloan A.E., Davis F.G., Vigneau F.D., Lai P., Sawaya R.E. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 2004, 22:2865-2872.
3. Nussbaum E.S., Djalilian H.R., Cho K.H., Hall W.A. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996, 78:1781-1788.
4. Amer M.H., Al-Sarraf M., Baker L.H., Vaitkevicius V.K. Malignant melanoma and central nervous system metastases: incidence, diagnosis, treatment and survival. Cancer 1978, 42:660-668.
5. Davies M.A., Liu P., McIntyre S., et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer 2011, 117:1687-1696.
6. Mathieu D., Kondziolka D., Cooper P.B., et al. Gamma knife radiosurgery for malignant melanoma brain metastases. Clin Neurosurg 2007, 54:241-247.
7. Fife K.M., Colman M.H., Stevens G.N., et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004, 22:1293-1300.
8. Sloan A.E., Nock C.J., Einstein D.B. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 2009, 16:248-255.
9. de la Monte S.M., Moore G.W., Hutchins G.M. Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983, 43:3427-3433.
10. Sampson J.H., Carter J.H., Friedman A.H., Seigler H.F. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88:11-20.
11. Raizer J.J., Hwu W.J., Panageas K.S., et al. Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features. Neuro Oncol 2008, 10:199-207.
12. Liew D.N., Kano H., Kondziolka D., et al. Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article. J Neurosurg 2011, 114:769-779.
13. Skeie B.S., Skeie G.O., Enger P.O., et al. Gamma knife surgery in brain melanomas: absence of extracranial metastases and tumor volume strongest indicators of prolonged survival. World Neurosurg 2011, 75:684-691. [discussion 598-603].
14. Lonser R.R., Song D.K., Klapper J., et al. Surgical management of melanoma brain metastases in patients treated with immunotherapy. J Neurosurg 2011, 115:30-36.
15. Radbill A.E., Fiveash J.F., Falkenberg E.T., et al. Initial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicity. Cancer 2004, 101:825-833.
16. Retsas S., Gershuny A.R. Central nervous system involvement in malignant melanoma. Cancer 1988, 61:1926-1934.
17. Staudt M., Lasithiotakis K., Leiter U., et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010, 102:1213-1218.
18. Flanigan J.C., Jilaveanu L.B., Faries M., et al. Melanoma brain metastases: is it time to reassess the bias?. Curr Probl Cancer 2011, 35:200-210.
19. McWilliams R.R., Brown P.D., Buckner J.C., Link M.J., Markovic S.N. Treatment of brain metastases from melanoma. Mayo Clin Proc 2003, 78:1529-1536.
20. Jakob J.A., Bassett R.L., Ng C.S., et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 2012, 118:4014-4023.
21. Redmond A.J., Diluna M.L., Hebert R., et al. Gamma Knife surgery for the treatment of melanoma metastases: the effect of intratumoral hemorrhage on survival. J Neurosurg 2008, 109(Suppl):99-105.
22. Patnana M., Bronstein Y., Szklaruk J., et al. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 2011, 66:224-236.
23. Yu C., Chen J.C., Apuzzo M.L., et al. Metastatic melanoma to the brain: prognostic factors after gamma knife radiosurgery. Int J Radiat Oncol Biol Phys 2002, 52:1277-1287.
24. Peruzzi P., Chiocca E.A. Prognosis and treatment of melanoma metastases to the central nervous system: lots of retrospective data, very few certainties. World Neurosurg 2011, 76:48-50.
25. Manon R., O'Neill A., Knisely J., et al. Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397). J Clin Oncol 2005, 23:8870-8876.
26. Morris S.L., Low S.H., A'Hern R.P., et al. A prognostic index that predicts outcome following palliative whole brain radiotherapy for patients with metastatic malignant melanoma. Br J Cancer 2004, 91:829-833.
27. Carella R.J., Gelber R., Hendrickson F., Berry H.C., Cooper J.S. Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma: Radiation Therapy Oncology Group Brain Metastases Study I and II. Cancer 1980, 45:679-683.
28. Kondziolka D., Patel A., Lunsford L.D., Kassam A., Flickinger J.C. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys 1999, 45:427-434.
29. Skibber J.M., Soong S.J., Austin L., Balch C.M., Sawaya R.E. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 1996, 3:118-123.
30. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
31. Sperduto P.W., Berkey B., Gaspar L.E., Mehta M., Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys 2008, 70:510-514.
32. Sperduto C.M., Watanabe Y., Mullan J., et al. A validation study of a new prognostic index for patients with brain metastases: the Graded Prognostic Assessment. J Neurosurg 2008, 109(Suppl):87-89.
33. Sperduto P.W., Chao S.T., Sneed P.K., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661.
34. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322:494-500.
35. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33:583-590.
36. Mintz A.H., Kestle J., Rathbone M.P., et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996, 78:1470-1476.
37. Muacevic A., Wowra B., Siefert A., Tonn J.C., Steiger H.J., Kreth F.W. Microsurgery plus whole brain irradiation versus Gamma Knife surgery alone for treatment of single metastases to the brain: a randomized controlled multicentre phase III trial. J Neurooncol 2008, 87:299-307.
38. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
39. Macdonald D.R., Cairncross J.G. Surgery for single brain metastasis. N Engl J Med 1990, 323:132-133.
40. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
41. Park H.S., Yu J.B., Knisely J.P.S., Chiang V.L.S. Outcomes following Gamma Knife for metastases. Gamma knife radiosurgery 2011, 3-28. InTech, Rijeka, Croatia. D. Mathieu (Ed.).
42. Park H.S., Chiang V.L., Knisely J.P., Raldow A.C., Yu J.B. Stereotactic radiosurgery with or without whole-brain radiotherapy for brain metastases: an update. Expert Rev Anticancer Ther 2011, 11:1731-1738.
43. Chang E.L., Wefel J.S., Hess K.R., et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044.
44. Aoyama H., Shirato H., Tago M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295:2483-2491.
45. Fogarty G., Morton R.L., Vardy J., et al. Whole brain radiotherapy after local treatment of brain metastases in melanoma patients-a randomised phase III trial. BMC Cancer 2011, 11:142.
46. Wadasadawala T., Gupta S., Bagul V., Patil N. Brain metastases from breast cancer: management approach. J Cancer Res Ther 2007, 3:157-165.
47. Zimm S., Wampler G.L., Stablein D., Hazra T., Young H.F. Intracerebral metastases in solid-tumor patients: natural history and results of treatment. Cancer 1981, 48:384-394.
48. Barranco S.C., Romsdahl M.M., Humphrey R.M. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 1971, 31:830-833.
49. Somaza S., Kondziolka D., Lunsford L.D., Kirkwood J.M., Flickinger J.C. Stereotactic radiosurgery for cerebral metastatic melanoma. J Neurosurg 1993, 79:661-666.
50. McWilliams R.R., Rao R.D., Brown P.D., Link M.J., Buckner J.C. Treatment options for brain metastases from melanoma. Expert Rev Anticancer Ther 2005, 5:809-820.
51. Knisely J., Kluger H., Flanigan J., Sznol M., Yu J., Chiang V. Primary radiosurgery for melanoma brain metastases in the ipilimumab era. J Neurosurg 2012, 117:227-233.
52. Rauch P.J., Park H.S., Knisely J.P., Chiang V.L., Vortmeyer A.O. Delayed radiation-induced vasculitic leukoencephalopathy. Int J Radiat Oncol Biol Phys 2012, 83:369-375.
53. Patel T.R., McHugh B.J., Bi W.L., Minja F.J., Knisely J.P., Chiang V.L. A Comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR Am J Neuroradiol 2011, 32:1885-1892.
54. Muldoon L.L., Soussain C., Jahnke K., et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25:2295-2305.
55. Aronow S. The use of radio-frequency power in making lesions in the brain. J Neurosurg 1960, 17:431-438.
56. Anzai Y., Lufkin R., DeSalles A., Hamilton D.R., Farahani K., Black K.L. Preliminary experience with MR-guided thermal ablation of brain tumors. AJNR Am J Neuroradiol 1995, 16:39-48. [discussion 49-52].
57. Menovsky T., Beek J.F., van Gemert M.J., Roux F.X., Bown S.G. Interstitial laser thermotherapy in neurosurgery: a review. Acta Neurochir (Wien) 1996, 138:1019-1026.
58. Kahn T., Bettag M., Ulrich F., et al. MRI-guided laser-induced interstitial thermotherapy of cerebral neoplasms. J Comput Assist Tomogr 1994, 18:519-532.
59. Ascher P.W., Justich E., Schrottner O. A new surgical but less invasive treatment of central brain tumours preliminary report. Acta Neurochir Suppl (Wien) 1991, 52:78-80.
60. Bettag M., Ulrich F., Schober R., et al. Stereotactic laser therapy in cerebral gliomas. Acta Neurochir Suppl (Wien) 1991, 52:81-83.
61. Carpentier A., McNichols R.J., Stafford R.J., et al. Real-time magnetic resonance-guided laser thermal therapy for focal metastatic brain tumors. Neurosurgery 2008, 63(Suppl 1). ONS21-8; discussion ONS8-9.
62. Roux F.X., Merienne L., Fallet-Bianco C., et al. Stereotaxic laser interstitial thermotherapy. A new alternative in the therapeutic management of some brain tumors. Neurochirurgie 1992, 38:238-244.
63. Sugiyama K., Sakai T., Fujishima I., Ryu H., Uemura K., Yokoyama T. Stereotactic interstitial laser-hyperthermia using Nd-YAG laser. Stereotact Funct Neurosurg 1990, 54-55:501-505.
64. Madajewicz S., West C.R., Park H.C., et al. Phase II study-intra-arterial BCNU therapy for metastatic brain tumors. Cancer 1981, 47:653-657.
65. Jacquillat C., Khayat D., Banzet P., et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 1990, 66:1873-1878.
66. Jacquillat C., Khayat D., Banzet P., et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 1990, 25:263-266.
67. Avril M.F., Aamdal S., Grob J.J., et al. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 2004, 22:1118-1125.
68. Agarwala S.S., Kirkwood J.M., Gore M., et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol 2004, 22:2101-2107.
69. Schadendorf D., Hauschild A., Ugurel S., et al. Dose-intensified bi-weekly temozolomide in patients with asymptomatic brain metastases from malignant melanoma: a phase II DeCOG/ADO study. Ann Oncol 2006, 17:1592-1597.
70. Amaravadi R.K., Schuchter L.M., McDermott D.F., et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin Cancer Res 2009, 15:7711-7718.
71. Majer M., Jensen R.L., Shrieve D.C., et al. Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 2007, 110:1329-1337.
72. Drummer R. An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases. J Clin Oncol 2011, 29. (Suppl; abstr 8548).
73. Lawrence D.P., Hamid O., McDermott O., et al. trial of ipilimumab monotherapy in melanoma patients with brain metastases. J Clin Oncol 2010, 28. (Suppl; abstr 8523).
74. Weber J.S., Amin A., Minor D., Siegel J., Berman D., O'Day S.J. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 2011, 21:530-534.
75. Hodi F.S., O'Day S.J., McDermott D.F., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
76. Di Giacomo A.M., Fonsatti E., Pittiglio E., et al. A phase II study combining ipilimumab and fotemustine in patients with metastatic melanoma: the NIBIT-M1 trial. J Clin Oncol 2011, 29. (Suppl; abstr TPS230).
77. Kefford R. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010, 28:15s. (Suppl; abstr 8503).
78. Middleton M.R., Grob J.J., Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000, 18:158-166.
79. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006, 24:4738-4745.
80. Chapman P.B., Einhorn L.H., Meyers M.L., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999, 17:2745-2751.
81. Atkins M.B., Kunkel L., Sznol M., Rosenberg S.A. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am 2000, 6(Suppl 1):S11-S14.
82. Robert C., Thomas L., Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
83. Rubinstein J.C., Sznol M., Pavlick A.C., et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010, 8:67.
84. Chapman P.B., Hauschild A., Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516.
85. Flaherty K.T., Puzanov I., Kim K.B., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010, 363:809-819.
86. Shen D.D., Artru A.A., Adkison K.K. Principles and applicability of CSF sampling for the assessment of CNS drug delivery and pharmacodynamics. Adv Drug Deliv Rev 2004, 56:1825-1857.
87. Potschka H. Targeting the brain-surmounting or bypassing the blood-brain barrier. Handb Exp Pharmacol 2010, 411-431.
88. Grimm S.A. Treatment of brain metastases: chemotherapy. Curr Oncol Rep 2012, 14:85-90.
89. Agarwala S.S., Kirkwood J.M. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000, 5:144-151.
90. Paul M.J., Summers Y., Calvert A.H., et al. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res 2002, 12:175-178.
91. Schartz N.E., Farges C., Madelaine I., et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res 2010, 20:247-250.
92. Hodi F.S., Oble D.A., Drappatz J., et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol 2008, 5:557-561.
93. Margolin K.A., Di Giacomo A.M., Maio M. Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy. Semin Oncol 2010, 37:468-472.
94. Weber J., Thompson J.A., Hamid O., et al. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 2009, 15:5591-5598.
95. Heller K.N. Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. J Clin Oncol 2011, 29. (Suppl; abstr 8581).
96. Kane R.C., Farrell A.T., Saber H., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006, 12:7271-7278.
97. Eisen T., Ahmad T., Flaherty K.T., et al. Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis. Br J Cancer 2006, 95:581-586.
98. Lorigan P., Chao D., Nathan P., et al. Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients. J Clin Oncol 2006, 24(June 20 Supplement):8012.
99. Long G.V. LBA27-Phase 1/2 study of GSK2118436, a selective inhibitor of V600 mutant (Mut) BRAF kinase: evidence of activity in melanoma brain metastases (Mets). ESMO 2010, 21(Suppl 8). Abstr LBA27.